Drug intelligence / Profile preview

CF2108

Development stage: Preclinical
Lead developer: Zhongke CELFULL

Overview

CF2108 is a therapeutic candidate being developed by Zhongke CELFULL Mitochondrial Medicine for the treatment of age-related sleep disorders. The drug is part of the company's mitochondrial medicine portfolio, which focuses on addressing health issues through the lens of mitochondrial function and cellular energy. While specific details regarding its molecular target and modality have not been disclosed, it is categorized as a therapeutic drug candidate rather than a nutraceutical. CF2108 is currently in the preclinical stage of development.

Beyond the preview

Go deeper on CF2108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF2108.

Explore the full profile